

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2023

NEUROENDOCRINE CANCER UK

PREVIOUSLY NET PATIENT FOUNDATION

LEGAL AND ADMINISTRATIVE INFORMATION

| | | |
|-----------------------------|---|---|
| Trustees | Dr R Srirajaskanthan Mr J Kent Mr T Jackson Mr P Gwilliam (Chairman) Mr D Bartlett Ms E Brown | (Appointed 21 November 2022) (Appointed 20 January 2023) |
| Charity number | 1092386 | |
| Principal address | Second Floor Holly House 74 Upper Holly Walk Leamington Spa Warwickshire CV32 4JL | |
| Independent examiner | Chapman Worth Limited 2 The Old Estate Yard High Street East Hendred Wantage Oxfordshire OX12 8JY | |
| Bankers | Lloyds Bank Butler Place Branch PO Box 100 BX1 1LT | |

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION CONTENTS

| | Page |
|-----------------------------------|-------------|
| Trustees' report | 1 - 5 |
| Independent examiner's report | 6 |
| Statement of financial activities | 7 |
| Statement of financial position | 8 |
| Notes to the financial statements | 9 - 19 |

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT

FOR THE YEAR ENDED 30 SEPTEMBER 2023

The Trustees are pleased to present the Trustees' Report and Accounts of Neuroendocrine Cancer UK (NCUK) for the year ended 30 September 2023. The Trustees are satisfied with the performance and progress of the charity during the year.

The accounts have been prepared in accordance with the accounting policies set out in Note 1 to the Accounts and comply with the Constitution of the charity, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives

The constitutional Objects of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognise, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness, and influencing improvements in outcomes.

The Values we believe in are: (i) equality of care for all neuroendocrine cancer patients in the UK, (ii) excellence in support, care, treatment, and research, (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types, (iv) collaborative working and building an accessible approachable fraternity, and (v) honesty, transparency, and integrity to promote confidence and trust in the charity.

Purpose and Need

NCUK exists to support and inform patients and families from diagnosis, enabling access to the best care and treatment, whilst stimulating neuroendocrine cancer research, increasing national awareness, and influencing improvements in outcomes.

A diagnosis of cancer is one of the greatest challenges anyone can face. Being diagnosed with a rare or uncommon cancer can have additional consequences, not least in terms of awareness, early diagnosis, and access to expertise. Feelings of isolation, fear, uncertainty, and anxiety are common.

We work hard as an evidence-based advocacy group, collecting real-life data from the community to drive change in both commissioning for neuroendocrine cancer treatments and clinical practice. Our advocacy role is focused on having true impact within a community unaware of the needs of neuroendocrine cancer patients. By sharing our knowledge and patient experience we can collaboratively create positive change. We want to enhance awareness and self-confidence within the patient community so they can make informed choices and ask questions. It is vital that the patient voice helps facilitate best practice, that alongside having an input into drug research and development, there is also a safe platform for sharing experiences and peer support.

2023 was a pivotal year for the organisation as it celebrated its 21st year. At the end of 2022/23 we have 12,405 subscribers to our database, an increase of 451 in the year. We have seen increases of 16% in our e-bulletin subscribers and 41.5% in our website users, with a dramatic rise of 108% in our website views. For comparison, we have seen a 23% increase on our Facebook page followers, a 30% increase on our Instagram page followers and a 17% increase on our Twitter page followers.

Our core and most costly service is our support service. The review of the demands on this service in terms of our helpline highlighted a dramatic increase, with the highest recorded contact forms in Q3 2023 since 2019. Key drivers for this are the current state of the NHS, which has left the patient community with more need for accessible support, and NCUK's efforts to increase its database, social media output and reach.

"I thought I could cope with most things in life, but the recent 6-8 week wait for a plan of action and MDT has very nearly finished me mentally. If I had not called the Helpline for an extensive discussion and support, I don't know what would have happened. I had simply reached my limit of what I could cope with mentally, starting awake in the middle of the night with an adrenaline shot of fear. My wonderful discussion on the Helpline led to me attending my first Natter that very evening. I thoroughly enjoyed talking to others who actually understood how I had been feeling. Thank you to Kate and Nikie."

Helpline user.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

Achievements and performance

The CEO is supported by the Trustee Board, a full-time (FT) and part-time (PT) specialist nurse, a cancer support coordinator (PT), 2 administrative assistants (PT), an operations and digital lead (FT), a campaigns lead (PT) and a communications officer (PT). NCUK's psychotherapy/counselling service is contracted to the Rareminds organisation, and we have freelance contractors supporting occasional projects, where we do not have the expertise or resource in-house.

A dedicated group of patient ambassadors also supports the work of the organisation. We have a reduced group at the time of writing due to illness and will be looking to recruit further ambassadors.

Hitting the 21-year milestone led to reflections and some adaptations to our 3-year strategy to ensure effectiveness and sustainability. NCUK's Strategic Aims are unchanged:

1. We act as a bridge between hospital and home.
2. We represent the voice of our community.
3. We build a collaborative community of people, knowledge, and expertise.
4. We support people affected by neuroendocrine cancer.
5. We strive to improve the patient pathway.

The following are the key achievements in 2022/23 for each of our Pillars of activity:

Advocacy and campaign work

Successful launch of our Spotlight campaign - a campaign to raise awareness and provide top-line education to HCPs who are not specialist in neuroendocrine cancer but are seeing neuroendocrine cancer patients. As an example, the GP arm of the campaign reached over 45,000 GPs with information about neuroendocrine cancer.

Successful launch of our Advancing Research campaign which exceeded the fundraising target of £50,000 in the first year.

Policy and political work

Successful launch of the 'first of its kind' ideal neuroendocrine cancer pathway for patients with neuroendocrine cancer of the gastrointestinal tract and lung.

Information provision

Delivery of our flagship patient information project in the form of an online, interactive handbook, which acts as a toolkit for anyone diagnosed and living with neuroendocrine cancer.

Educational programmes

Launch of our strategically-planned national education webinar series (N.E.W.S):

- Free events to empower and educate patients about all aspects of neuroendocrine cancer
- Invaluable support, knowledge, and sense of community for those affected
- Talks delivered by expert HCP faculty
- Interactive workshops, panel discussions, clinical lectures
- Talks are filmed and available online
- 1 meeting every 3 months across all UK regions.

Awareness and comms activity

Development of our podcast series – Not Just NE Cancer:

- A podcast covering real life experiences, practical advice & everything in-between
- Interviews with HCPs, organisations & those living with the condition
- Topics from initial diagnosis, treatments and follow up, looking after your mental health and professional perspectives
- Podcast 'take-overs' to focus on specific areas e.g., research.

This podcast was voted number 9 in the 40 best UK cancer podcasts.

Support service work

Running 300 support meetings throughout the budget year, supporting the largest population of patients and family members since our inception and developing our psychotherapy service to include two separate group sessions for those just diagnosed and living with neuroendocrine cancer.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2023

Note from the CEO Cathy Bouvier Ellis

We support all those affected by neuroendocrine cancer through our support and information work, we influence infrastructure and optimal care through our advocacy and policy work, and we address public perceptions of neuroendocrine cancer through our education and awareness work.

We do this because, although we have seen an increased knowledge and understanding with respect to classification, pathogenesis, treatment, and research regarding neuroendocrine cancers, and we have seen the growth of patient advocacy and real-world data about the lived experience of the patient community, we have also witnessed, heard and listened to the significant challenges a newly diagnosed patient has to contend with - a sense of being invisible, surrounded by the unfamiliar, especially terminology, diagnostics and treatments, not conforming to the 'treatment, recovery and survivorship/decline' model of cancer care, coping with uncertainty and ultimately having to live with cancer.

Our key commitments for 2022-2025 are to educate, inform, support and influence 5 key target groups: our community, the public, social/welfare organisations, the clinical community, and policy/political decision makers.

There are 12 key activities laid out below to ensure alignment, optimum impact, and success. Each activity has been grouped under one of our 3 workplans.

External workplan

- a. Continue to grow our community through strong outreach and campaign work - match our perceived impact numbers to our database figures
- b. Develop and encourage collaborative projects around educational initiatives to share resource and funds
- c. Complete, drive and integrate our vital policy work on the neuroendocrine cancer patient pathway and National Access Plan
- d. Optimise our 'shop front' website and patient materials, with a focus on ease of access and accessibility for all.

Internal workplan

- e. Revising current external workplan to prioritise key outputs for the next 3 years based on robust plans, realistic timelines, and adequate budget. This has been adapted to reflect learnings from 2022/2023
- f. Revise and simplify our current campaign work to ensure maximum transparency, readability, focus and impact
- g. Develop deliverable and targeted communications and digital strategies
- h. Revisiting our organisational structure to maximise skills and capability and to understand the organisational resource gaps
- i. Increase and optimise the use of current data and digital technologies for improved reporting and data management
- j. Complete a Trustee review, increase the Trustee board, and review current Trustee policies and procedures. The Trustee review is planned for the November 2023 Trustee meeting and all paperwork delivered to Trustees for completion.

Funding Workplan

- k. Develop a strong financial plan and budget, with key coding references that mirror the activities of the organisation and preparation for any foreseen economic difficulties
- l. Increase and diversify our income streams.

This year has had its challenges, with the amount of work we had planned, the demands foreseen and unforeseen, requests to the organisation for support and the complexity of the disease area we specialise in. This has led to a workforce that is certainly feeling the pressure placed upon it. Third sector organisations across the UK are feeling such pressure and demands, with very little support, and the next year will be planned with this in mind.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

Financial review

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £61,439 (2022 £11,244) for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the Trustees.

At the reporting date the charity held funds of £750,214 (2022 £688,775) and the Trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. NCUK receives income through donations and, less regularly, through grants and legacies. Expenditure comprises regular operating costs and project costs. Our reserves policy is to keep reserves to cover 1.5 to 2 years' budgeted regular operating costs.

Structure, governance and management

The NET Patient Foundation was established on 21 February 2001. Its governing document is a Constitution which was adopted on that date and has been amended on a number of occasions subsequently. On 25 June 2013 the name of the charity was shortened to NET Patient Foundation removing the words "incorporating Living with Carcinoid". On 12 December 2019 the name of the charity was changed to Neuroendocrine Cancer UK.

The Objectives of the charity were amended on 5 December 2013 to more simply reflect its principal aims as follows:

- (i) To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs.
- (ii) To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

| | |
|--------------------------|------------------------------|
| Mrs R Littlejohn | (Resigned 16 March 2023) |
| Dr R Srirajaskanthan | |
| Mrs I Wotherspoon | (Resigned 14 February 2023) |
| Mr J Kent | |
| Mr T Jackson | |
| Mr P Gwilliam (Chairman) | |
| Mr D Bartlett | (Appointed 21 November 2022) |
| Ms E Brown | (Appointed 20 January 2023) |

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new trustees.

The Trustees have a range of skills and experience and they meet regularly with the CEO of the charity to develop strategy, discuss and agree objectives and subsequently to establish whether the strategy has been implemented and the objectives have been achieved.

The charity enlists the support of volunteers for various projects such as patient input into NCRI neuroendocrine sub-group meetings, national NCUK projects and awareness raising activities such as NET Cancer Day. It also uses a bank of consultants for PR and media support, and psychotherapy services for patients and family members.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
TRUSTEES' REPORT (CONTINUED)**

FOR THE YEAR ENDED 30 SEPTEMBER 2023

In addition NCUK is supported by an expert Advisory Board which is an inter-disciplinary group of specialists (doctors, nurses and allied health care professionals including dieticians and counsellors) who all have a wealth of experience working with neuroendocrine cancer. This Board was established to provide expert advice, to promote and ensure effective, accessible, equitable and evidence-based health care and to provide information on current and future developments in neuroendocrine cancer care. The areas of clinical competence and expertise provided by members of this Board include primary, hospital and community care, pharmaceuticals, dietetics, research and development, health promotion and health education. Board members are based primarily but not exclusively in the fields of gastroenterology, surgery, endocrinology, radiology, nuclear medicine and oncology. Advisory Board members are on hand to answer any patient queries which the NCUK team cannot resolve.

The Trustees confirm that they have followed the Charity Commission's general guidelines on public benefit in undertaking their activities. All Trustees are aware of the Charity Commission Public Benefit Guidance (September 2013).

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new Trustees.

The Trustees report was approved by the Board of Trustees.



.....
Mr P Gwilliam (Chairman)
Trustee

Date: 06/02/2024

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF NEUROENDOCRINE CANCER UK**

I report to the Trustees on my examination of the financial statements of Neuroendocrine Cancer UK (the charity) for the year ended 30 September 2023.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Anna Chapman FCA
Chapman Worth Limited
2 The Old Estate Yard
High Street
East Hendred
Wantage
Oxfordshire
OX12 8JY

Dated: 6/2/2024

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 30 SEPTEMBER 2023

| | | Unrestricted funds 2023 £ | Restricted funds 2023 £ | Total 2023 £ | Total 2022 £ |
|---|-------|------------------------------------|----------------------------------|--------------------|--------------------|
| | Notes | | | | |
| <u>Income from:</u> | | | | | |
| Donations and legacies | 3 | 472,828 | 14,195 | 487,023 | 348,111 |
| Grants | 4 | - | 2,300 | 2,300 | 50,424 |
| Investments | 5 | 2,885 | - | 2,885 | 230 |
| Total income | | 475,713 | 16,495 | 492,208 | 398,765 |
| <u>Expenditure on:</u> | | | | | |
| Raising funds | 6 | 2,637 | - | 2,637 | 11,834 |
| Charitable activities | 7 | 369,982 | 58,149 | 428,131 | 375,687 |
| Total resources expended | | 372,619 | 58,149 | 430,768 | 387,521 |
| Net incoming/(outgoing) resources before transfers | | 103,094 | (41,654) | 61,440 | 11,244 |
| Gross transfers between funds | | (3,520) | 3,520 | - | - |
| Net income/(expenditure) for the year/ Net movement in funds | | 99,574 | (38,134) | 61,440 | 11,244 |
| Fund balances at 1 October 2022 | | 641,697 | 47,078 | 688,775 | 677,531 |
| Fund balances at 30 September 2023 | | 741,271 | 8,944 | 750,215 | 688,775 |

The statement of financial activities includes all gains and losses recognised in the year.


All income and expenditure derive from continuing activities.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
STATEMENT OF FINANCIAL POSITION**

AS AT 30 SEPTEMBER 2023

| | Notes | 2023 £ | £ | 2022 £ | £ |
|---|-------|----------------|----------------|----------------|----------------|
| Current assets | | | | | |
| Debtors | 13 | 571 | | 16,192 | |
| Cash at bank and in hand | | 759,909 | | 686,515 | |
| | | <u>760,480</u> | | <u>702,707</u> | |
| Creditors: amounts falling due within one year | 14 | (10,265) | | (13,932) | |
| Net current assets | | | <u>750,215</u> | | <u>688,775</u> |
| Income funds | | | | | |
| Restricted funds | 15 | | 8,944 | | 47,078 |
| Unrestricted funds - general | | | 741,271 | | 641,697 |
| | | | <u>750,215</u> | | <u>688,775</u> |

The financial statements were approved by the Trustees on 06/02/2024


.....
Mr P Gwilliam (Chairman)
Trustee

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

Charity information

Neuroendocrine Cancer UK is a unincorporated charity in England and Wales (charity number: 1092386) providing support and information to people affected by neuroendocrine cancers. The charity's address is: Second floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

(Continued)

1.5 Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

The costs of generating funds consist of fund-raising event costs and associated merchandise and fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

Allocation of support costs

Support costs have been allocated on a basis of estimation that the cost was incurred to support the charity's objectives. These judgements are made by the board of trustees to reflect the actual costs incurred in supporting the charity. See note 10 to the accounts which show the critical judgements made by the trustees and show the estimated costs that are deemed attributable to the charity's overheads.

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

3 Donations and legacies

| | Unrestricted funds general 2023 £ | Restricted funds 2023 £ | Total 2023 £ | Total 2022 £ |
|---|---|----------------------------------|--------------------|--------------------|
| Donations and gifts | 448,030 | 14,195 | 462,225 | 347,391 |
| Legacies receivable | 24,798 | - | 24,798 | 720 |
| | <u>472,828</u> | <u>14,195</u> | <u>487,023</u> | <u>348,111</u> |
| For the year ended 30 September 2022 | <u>315,826</u> | <u>32,285</u> | | <u>348,111</u> |

4 Grants

| | Society for Endocrine 2023 £ | Total 2023 £ | Ipsen 2022 £ | AAA 2022 £ | Total 2022 £ |
|----------------------------|---------------------------------------|--------------------|--------------------|------------------|--------------------|
| Performance related grants | <u>2,300</u> | <u>2,300</u> | <u>25,424</u> | <u>25,000</u> | <u>50,424</u> |

5 Investments

| | Unrestricted funds general 2023 £ | Total 2022 £ |
|---------------------|---|--------------------|
| Interest receivable | <u>2,885</u> | <u>230</u> |

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

6 Raising funds

| | Unrestricted funds general 2023 £ | Total 2022 £ |
|----------------------------------|--|-----------------------------|
| <u>Fundraising and publicity</u> | | |
| Other fundraising costs | 2,637 | 11,834 |
| | <u>2,637</u> | <u>11,834</u> |

7 Charitable activities

| | 2023 £ | 2022 £ |
|--|-------------------|-------------------|
| Staff costs | 153,597 | 137,452 |
| Strategic Activities | 122,741 | 85,354 |
| Computer costs | 11,084 | 8,521 |
| Advertising and marketing | 4,774 | 1,429 |
| Travel and subsistence | 4,417 | 2,045 |
| Telephone | 2,850 | 3,771 |
| Office expenses | 8,187 | 6,541 |
| Legal and professional | 3,800 | 6,123 |
| Other costs | 330 | 1,960 |
| | <u>311,780</u> | <u>253,196</u> |
| Grant funding of activities (see note 9) | 7,115 | 26,475 |
| Share of support costs (see note 10) | 105,379 | 91,925 |
| Share of governance costs (see note 10) | 3,857 | 4,091 |
| | <u>428,131</u> | <u>375,687</u> |
| Analysis by fund | | |
| Unrestricted funds - general | 369,982 | 330,308 |
| Restricted funds | 58,149 | 45,379 |
| | <u>428,131</u> | <u>375,687</u> |

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

8 Description of charitable activities

The charitable activities are to inform people to recognise, diagnose, treat, care for, and ultimately cure people with Neuroendocrine cancer. All activity costs above are the direct charitable costs in achieving these charitable objectives.

9 Grants paid

| | 2023 | 2022 |
|----------------------|--------------|---------------|
| NCUK Virtual Toolkit | 7,088 | 3,163 |
| NCRAS Project | - | 23,312 |
| NCUK Life Alliance | 27 | - |
| | <u>7,115</u> | <u>26,475</u> |

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

10 Support costs

| | Support costs | Governance costs | 2023 | Support costs | Governance costs | 2022 | Basis of allocation |
|---------------------------|----------------|------------------|----------------|---------------|------------------|---------------|------------------------------|
| | £ | £ | £ | £ | £ | £ | |
| Staff costs | 86,137 | - | 86,137 | 51,569 | - | 51,569 | Administrative staff |
| Office expenses | 1,208 | - | 1,208 | 6,325 | - | 6,325 | 13% of the cost (2022 32%) |
| Legal and professional | 2,854 | - | 2,854 | 3,874 | - | 3,874 | 43% of the cost (2022 77%) |
| Computer costs | 1,666 | - | 1,666 | 5,328 | - | 5,328 | 13% of the cost (2022 39%) |
| Advertising and marketing | - | - | - | 612 | - | 612 | 0% of the cost (2022 30%) |
| Rent and rates | 12,643 | - | 12,643 | 23,348 | - | 23,348 | 100% of the cost (2022 100%) |
| Telecommunications | 186 | - | 186 | 419 | - | 419 | 6% of the cost (2022 10%) |
| Other costs | 685 | - | 685 | 450 | - | 450 | 67% of the cost (2022 25%) |
| Accountancy fees | - | 3,857 | 3,857 | - | 4,091 | 4,091 | Governance |
| | <u>105,379</u> | <u>3,857</u> | <u>109,236</u> | <u>91,925</u> | <u>4,091</u> | <u>96,016</u> | |
| Analysed between | | | | | | | |
| Charitable activities | <u>105,379</u> | <u>3,857</u> | <u>109,236</u> | <u>91,925</u> | <u>4,091</u> | <u>96,016</u> | |

Each member of staff has specific roles and responsibilities to fulfil and support the charity's objectives. Each member of staff is either allocated to frontline duties or placed in a supporting role which aids those staff to fulfil the charity's objectives.

Judgements are made by the trustees to allocate a percentage of resources to support costs that accurately reflect the time and resources spent in supporting the charities objectives. The estimation techniques can be seen in the note above and are specific to the charity's activities.

Governance costs include payments to the independent examiners of £1,986 (2022- £1,872) for independent examination fees.

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

11 Trustees

None of the Trustees (or any persons connected with them) received any reimbursed expenses during the year.

12 Employees

The average monthly number of employees during the year was:

| | 2023 | 2022 |
|--|-------------------|-------------------|
| | Number | Number |
| | 9 | 9 |
| | <u> </u> | <u> </u> |

Employment costs

| | 2023 | 2022 |
|-----------------------|-------------------|-------------------|
| | £ | £ |
| Wages and salaries | 216,160 | 172,462 |
| Social security costs | 19,094 | 12,665 |
| Other pension costs | 4,480 | 3,894 |
| | <u> </u> | <u> </u> |
| | 239,734 | 189,021 |
| | <u> </u> | <u> </u> |

The number of employees whose annual remuneration was more than £60,000 is as follows:

| | 2023 | 2022 |
|--------------------|-------------------|-------------------|
| | Number | Number |
| > £60,000 | 1 | 1 |
| £10,000 to £60,000 | 8 | 8 |
| | <u> </u> | <u> </u> |

13 Debtors

| | 2023 | 2022 |
|---|-------------------|-------------------|
| | £ | £ |
| Amounts falling due within one year: | | |
| Trade debtors | 1 | 12,500 |
| Other debtors | 410 | 3,692 |
| Prepayments and accrued income | 160 | - |
| | <u> </u> | <u> </u> |
| | 571 | 16,192 |
| | <u> </u> | <u> </u> |

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

14 Creditors: amounts falling due within one year

| | 2023 | 2022 |
|------------------------------------|---------------|---------------|
| | £ | £ |
| Other taxation and social security | 4,629 | 5,360 |
| Trade creditors | 1,007 | 5,441 |
| Other creditors | 2,643 | 1,259 |
| Accruals and deferred income | 1,986 | 1,872 |
| | <u>10,265</u> | <u>13,932</u> |

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

15 Restricted funds

The Income Funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

| | Balance at October 2021 | Incoming resources | Movement in funds | | Balance at 30 September 2023 |
|---|----------------------------|--------------------|--------------------|--------------|------------------------------------|
| | £ | £ | Resources expended | Transfers | £ |
| AAA - Data Extraction / Medical Writing Project | 478 | - | - | - | 478 |
| AAA - NCUK Summit | 5,216 | - | - | - | 5,216 |
| AAA - Patient Travel / Welfare Support | 3,675 | - | (2,425) | - | 1,250 |
| Ipsen - Pathway Project | 25,424 | 300 | (25,724) | - | - |
| Advanced Research | 12,285 | 14,195 | (30,000) | 3,520 | - |
| Society for Endocrine | - | 2,000 | - | - | 2,000 |
| | <u>47,078</u> | <u>16,495</u> | <u>(58,149)</u> | <u>3,520</u> | <u>8,944</u> |

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

16 Analysis of net assets between funds

| | Unrestricted funds 2023 £ | Restricted funds 2023 £ | Total 2023 £ | Unrestricted funds 2022 £ | Restricted funds 2022 £ | Total 2022 £ |
|--|------------------------------------|----------------------------------|--------------------|------------------------------------|----------------------------------|--------------------|
| Fund balances at 30 September 2023 are represented by: | | | | | | |
| Current assets/(liabilities) | 741,271 | 8,944 | 750,215 | 641,697 | 47,078 | 688,775 |
| | <u>741,271</u> | <u>8,944</u> | <u>750,215</u> | <u>641,697</u> | <u>47,078</u> | <u>688,775</u> |

17 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

| | 2023 £ | 2022 £ |
|------------------------|---------------|---------------|
| Aggregate compensation | <u>66,572</u> | <u>65,613</u> |